Although prior systemic reviews have been conducted, these studies do not speak to HER2 targeting agents developed since trastuzumab and lapatinib, and one is not restricted to patients with HER2-positive disease.28,29 Our understanding of outcomes among patients with HER2-positive breast cancer brain metastases who receive HER2-targeted therapy thus remains limited. Here, ERBB2 is linked to breast carcinoma.